Arketamine – Kodiac biolabs

Plain-language summaryIntrigue 78 / 100

Arketamine is the R-enantiomer of ketamine (the other half of the racemate). Animal studies suggest the antidepressant effects may be longer-lasting than esketamine with fewer dissociative side effects. Investigated as an alternative depression treatment. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

58/100

Enantiomeric ketamine with a compelling TrkB-over-NMDA mechanism story and active phase 2 clinical development

Here’s the thing about arketamine: the pharmacology is more interesting than the name implies. Everyone knows ketamine; a lot of people now know esketamine (Spravato). R-ketamine sits in a genuinely strange position, which is lower NMDA receptor affinity than its (S)-sibling, yet rodent models consistently show more durable antidepressant effects and a reduced dissociative burden. That paradox is exactly where the interesting science lives.

The mechanism story has sharpened considerably over the last few years. Kenji Hashimoto’s lab at Chiba University built a series of papers arguing that arketamine’s antidepressant action leans harder on downstream signaling, specifically BDNF/TrkB pathway activation and mGluR modulation, than on acute NMDA channel blockade. The 2021 Casarotto et al. work in Cell added broader context: TrkB is a direct binding target for ketamine-class molecules, and the two enantiomers differ meaningfully in their TrkB-to-NMDA affinity ratio. That mechanistic wedge is what makes arketamine scientifically interesting rather than just a stereochemical footnote.

What we like here is the probe utility. If you want to dissect NMDA-dependent from TrkB-dependent antidepressant mechanisms, running parallel R versus S experiments is one of the cleaner designs available. The enantiomeric comparison opens questions that neither compound answers alone. Thats valuable even if arketamine never clears phase 3. For investigators working on NMDA receptor biology, synaptic plasticity, or rapid-acting antidepressant mechanisms, this is a tool worth having access to.

The differentiation story versus esketamine is compelling but not closed. Esketamine has FDA approval, a defined clinical niche in treatment-resistant depression and acute suicidality, and market infrastructure. Arketamine’s pitch is fewer dissociative effects plus potentially more sustained efficacy, a profile that would matter enormously for outpatient use and treatment adherence. Perception Neuroscience is running phase 2 trials. The preclinical case is solid; the human case is early and needs legs.

Evidence quality is the honest constraint. Hashimoto’s group dominates arketamine’s preclinical literature in a way that echoes the BPC-157 situation: strong signal from one sophisticated lab that needs broader independent replication. Early phase 2 human readouts are encouraging but have not yet been confirmed across multiple independent trial groups. We want to see that before the evidence score moves.

Scheduling matters for access: as a ketamine enantiomer, arketamine carries Schedule III status, which shapes institutional access and researcher infrastructure. Not a dealbreaker for programs already handling ketamine, but it narrows the field. Overall this sits in a genuinely interesting corner of depression pharmacology, and the enantiomeric probe value alone justifies attention from serious NMDA or neuroplasticity programs.

Novelty: 60
Mechanism promise: 72
In-category differentiation: 55
Evidence quality: 45
Translational signal: 48
Research bench value: 65

Rationale Arketamine scores well on mechanism because the enantiomeric differentiation from esketamine is pharmacologically meaningful and the TrkB/BDNF angle is supported by multi-lab work; evidence and translational scores are held back by Hashimoto-lab dominance in the preclinical literature and phase 2 data that lacks cross-group replication.

R-enantiomer NMDA antagonist

The (R)-enantiomer of ketamine, currently in clinical development for depression with reportedly more sustained antidepressant action and fewer dissociative effects.

Abstract

Arketamine (R-ketamine; CAS 33643-47-9) is the (R)-enantiomer of ketamine, currently in clinical development by Perception Neuroscience and others. The (R)-enantiomer has lower NMDA receptor affinity than the (S)-enantiomer (esketamine), but rodent data suggest more sustained antidepressant effects with reduced dissociative side effects. Phase 2 trials are ongoing. Mechanism includes NMDA modulation but with secondary mechanisms (BDNF/TrkB pathway, mGluR effects) that may underlie the differential clinical profile. Not currently FDA approved.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-172Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.